<DOC>
	<DOCNO>NCT03055026</DOCNO>
	<brief_summary>Rivaroxaban placebo extend antithrombotic prophylaxis laparoscopic surgery colorectal cancer : randomize , double blind , placebo-controlled study .</brief_summary>
	<brief_title>Rivaroxaban Placebo Extended Antithrombotic Prophylaxis After Laparoscopic Surgery Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Objective diagnosis colorectal cancer ; Elective laparoscopic surgery colorectal cancer Whatever stage cancer Antithrombotic prophylaxis LMWH administer 7Â±2 day surgery Age &lt; 18 year Surgery noncancer disease Duration surgery &lt; 45 min Conversion open surgery Other indication anticoagulant therapy Known cerebral metastasis Kidney liver failure Known hemorrhagic diathesis high risk bleed History intracerebral bleeding neurosurgery within 6 month History heparin induce thrombocytopenia Pregnancy lactation Refusal inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>